Erschienen in:
01.12.2021 | Esophagus (J Clarke and N Ahuja, Section Editors)
Innovations in Screening Tools for Barrett’s Esophagus and Esophageal Adenocarcinoma
verfasst von:
Matthew G. Bell, Prasad G. Iyer
Erschienen in:
Current Gastroenterology Reports
|
Ausgabe 12/2021
Einloggen, um Zugang zu erhalten
Abstract
Purpose of Review
Esophageal adenocarcinoma (EAC) is a lethal disease with rapidly rising incidence. Screening for EAC and its metaplastic precursor, Barrett’s esophagus (BE), followed by endoscopic surveillance and endoscopic treatment of dysplasia or early EAC are promising approaches to decreasing EAC incidence and EAC mortality. Historically, screening for EAC has been completed with a traditional per-oral esophagogastroduodenoscopy (EGD); however, this method has limitations including cost, tolerability, and accessibility. For this reason, much effort has been put forward to develop more effective, minimally invasive, and accessible BE and EAC screening tools. The purpose of this review is to describe recent developments of these novel tools.
Recent Findings
While endoscopic alternatives such as transnasal endoscopy are cheaper and well tolerated, they have not gained acceptance. Non-endoscopic modalities namely, swallowable cell collection devices coupled with biomarker analysis have been found to have excellent performance characteristics, tolerability, and cost effectiveness.
Summary
In this article, we provide an update on innovative developments in EAC/BE screening modalities including transnasal endoscopy, capsule endomicroscopy, swallowable cell collection devices, and exhaled volatile organic compound analyses.